Biovitrum AB has taken a significant step in its goal to become a fully integrated, specialty pharmaceutical firm focused on niche indications, with an SEK3.656 billion (US$533.1 million) cash-and-shares acquisition of Swedish Orphan International AB. (BioWorld International)